Summary - NVS - NYSE - Weiss Ratings

C

Novartis AG NVS

$105.85 -$6.41-5.71%

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

52-Week Range

$92.35 - $120.92

P/E (TTM)

EPS (TTM)

My Lists My Alerts

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

Novartis AG (NYSE:NVS) Shares Sold by Somerville Kurt F

4/6/2025 - MarketBeat

Novartis After Sandoz: The Business Without Generics

4/6/2025 - Seeking Alpha - Long Ideas

Novartis After Sandoz: The Business Without Generics

4/6/2025 - SeekingAlpha

Novartis (NYSE:NVS) Shares Gap Up - Here's Why

4/5/2025 - MarketBeat

Pitcairn Co. Increases Position in Novartis AG (NYSE:NVS)

4/5/2025 - Ticker Report

Novartis AG (NVS) Shares Gap Down to $107.0401 on Apr 4

4/4/2025 - GuruFocus

NVS Makes Notable Cross Below Critical Moving Average

4/4/2025 - Market News Video

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

4/4/2025 - Zacks Investment Research

Puzo Michael J Decreases Holdings in Novartis AG (NYSE:NVS)

4/4/2025 - Ticker Report

Novartis AG (NYSE:NVS) Shares Sold by Martin Investment Management LLC

4/4/2025 - MarketBeat

Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the ...

4/3/2025 - GuruFocus

Blackstone Inc (BX) Announces Novartis' Acquisition of Anthos Therapeutics for Up to $3.1 Billion

4/3/2025 - GuruFocus

Novartis price target raised to CHF 115 from CHF 110 at Deutsche Bank

4/3/2025 - TipRanks Financial Blog

Novartis price target raised by CHF 5 at Deutsche Bank

4/3/2025 - The Fly

Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year

4/3/2025 - Benzinga

FDA Grants Accelerated Approval to NVS Kidney Disease Drug

4/3/2025 - Zacks Investment Research

Novartis Pops Hammering Rival Travere Therapeutics On Its Kidney Drug Approval

4/3/2025 - Investor's Business Daily

Novartis gets FDA accelerated approval for kidney disease treatment

4/3/2025 - Seeking Alpha - Healthcare

Deutsche Bank Remains a Buy on Novartis AG (NOVN)

4/3/2025 - TipRanks Financial Blog

vanrafia 2nd novartis drug igan troika crosses fda finish line payday chinook investors

4/3/2025 - FiercePharma

European, Asian pharma stocks rally as Trump spares sector from reciprocal tariffs but the cheer may be shortlived

4/3/2025 - Invezz News

Novartis AG (NYSE:NVS) Shares Sold by Wellington Management Group LLP

4/3/2025 - MarketBeat

beigene abandons ociperlimab over poor phase 3 prospects latest blow tigits

4/3/2025 - FierceBiotech.com - Biotech

Novartis AG (NYSE:NVS) Sees Significant Decrease in Short Interest

4/3/2025 - Ticker Report

novartis receives fda accelerated approval for vanrafia atrasentan the first and only selective endothelin a receptor antagonist for proteinuria reduction in primary iga nephropathy igan

4/3/2025 - GuruFocus

Income Statement

Total Revenue (TTM)

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Friday, January 31, 2025

Period Date

Tuesday, December 31, 2024

Next Filing

Week of Apr 21 and 25 (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

52-week Low

Apr 18, 2024 - $92.35

52-week High

Aug 30, 2024 - $120.92

Valuation

Market Cap

$203.46B - Mega Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

Dividend Per Share (TTM)

Corporate Info

Website

www.novartis.com

Phone Number

41 61 324 11 11

Address

Lichtstrasse 35
Basel, 4056

Country

Year Founded

Business Description

Sector

--

Industry

--

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an... more